Application value of HR-HPV DNA combined with TCT in the screening of cervical precancerous lesions
Objective To analyze the application value of high risk human papilloma virus DNA(HR-HPV DNA)combined with thinprep cytology test(TCT)in the screening of cervical precancerous lesions.Methods A total of 1 374 women who received screening for cervical precancerous lesions in the gynecological clinic of our hospital from January to December 2022 were selected as the research objects.All research objects underwent TCT,HR-HPV DNA and histopathological examination.The results of TCT and HR-HPV DNA alone and combined examination were analyzed and the diagnostic efficacy was compared with the results of histopathological examination as the gold standard.Results The results of pathological examination showed that 184 cases of 1 374 women were positive,with a detection rate of 13.39%.Among the 1 374 women,180 positive patients were detected by TCT examination,and the positive detection rate was 13.10%;195 positive patients were detected by HR-HPV DNA examination,and the positive detection rate was 14.19%;191 positive patients were detected by TCT combined with HR-HPV DNA examination,and the positive detection rate was 13.90%.The diagnostic sensitivity,specificity,accuracy,positive predictive value and negative predictive value of TCT combined with HR-HPV DNA examination were higher than those of HR-HPV DNA examination(P<0.05);the diagnostic sensitivity,accuracy and negative predictive value of TCT combined with HR-HPV DNA examination were higher than those of TCT examination(P<0.05);there were no significant differences in diagnostic specificity and positive predictive value between TCT,HR-HPV DNA combined examination and TCT examination(P>0.05).Conclusion HR-HPV DNA combined with TCT examination applied in the screening of cervical precancerous lesions can improve the efficiency and provide accurate reference for the early diagnosis of doctors,which is worthy of promotion.
NETL
NSTL
万方数据
